The partnership is expected to help the two firms launch a product that will include Thorne HealthTech’s OneDraw DNA cartridges and the GenSolve technology of GenTegra for highly efficient extraction of DNA

dna-5297378_640

Thorne HealthTech joins forces with GenTegra to develop whole blood DNA collection and extraction kit. (Credit: Mahmoud Ahmed from Pixabay)

US-based wellness company Thorne HealthTech has announced a collaboration with GenTegra with an aim to build a whole blood DNA collection cartridge and a comprehensive stabilisation and extraction kit.

For this, GenTegra’s patented Active Chemical Protection technology and Thorne HealthTech’s OneDraw collection device will be utilised.

The collaboration is expected to help the two firms launch a product that will be inclusive of Thorne HealthTech’s OneDraw DNA cartridges and the GenSolve technology of GenTegra for highly efficient DNA extraction.

According to Thorne HealthTech, the cartridges will be featuring cold-chain-free preservation of DNA in combination with DNA extraction technology. The company expects the lab testing kits to benefit users as well as labs that process the samples.

GenTegra president Bob Barrett said: “GenTegra’s Active Chemical Protection technology is utilised across a broad range of life science applications to stabilize and protect DNA and RNA from a variety of sample types.

“We’re encouraged by the progress and successes we’ve been testing and are looking forward to working with Thorne and its OneDraw device and cartridge to further enhance DNA preservation and extraction for remote patient sample collection.”

In a recent study, GenTegra showed that its Active Chemical Protection technology can be applied to the cold-chain-free blood storage matrix of OneDraw’s blood collection device for further preservation of DNA at room temperature.

Furthermore, GenTegra’s GenSolve reagent kit for laboratories, enabled the extraction of larger quantities of high-quality DNA from whole blood collection matrices.

Thorne HealthTech CEO Paul Jacobson said: “Sample collection is a critical component of delivering accurate test results to the end user.

“From collection to analysis, GenTegra’s powerful chemistry, combined with a cold-chain-free storage platform, provides a huge opportunity for our product to be deployed into numerous healthcare fields to improve user experience and reach more people with the same degree of sample integrity and accuracy in market today.”